Evidence map›Paper›PMID 40985020›Full record

ArticleSurgical case reports2025

A Case of T1bN0 Esophageal Squamous Cell Carcinoma That Developed Recurrence 7 Years after Curative Esophagectomy.

Shinichiro Shiomi, Takashi Fukuda, Shintaro Nozu, Daiji Oka, Yusuke Yoda, Noriko Motoi, Hiroaki Kanda

Abstract readCase Reports
In one paragraph

Article in Surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shinichiro ShiomiDepartment of Gastroenterological Surgery, Saitama Cancer Center Hospital, Kitaadachi-gun, Saitama, Japan.
Takashi FukudaDepartment of Gastroenterological Surgery, Saitama Cancer Center Hospital, Kitaadachi-gun, Saitama, Japan.
Shintaro NozuDepartment of Gastroenterological Surgery, Saitama Cancer Center Hospital, Kitaadachi-gun, Saitama, Japan.
Daiji OkaDepartment of Gastroenterological Surgery, Saitama Cancer Center Hospital, Kitaadachi-gun, Saitama, Japan.
Yusuke YodaDepartment of Gastroenterological Endoscopy, Saitama Cancer Center Hospital, Kitaadachi-gun, Saitama, Japan.
Noriko MotoiDepartment of Pathology, Saitama Cancer Center Hospital, Kitaadachi-gun, Saitama, Japan.
Hiroaki KandaDepartment of Pathology, Saitama Cancer Center Hospital, Kitaadachi-gun, Saitama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe optimal follow-up period and appropriate examinations for patients with esophageal squamous cell carcinoma (ESCC) who have remained disease-free for 5 years remain controversial. CASE PRESENTATION: A 73-year-old man was diagnosed with ESCC and underwent curative esophagectomy. Pathological examination revealed a superficial tumor without lymph node metastases, despite lymphatic and vascular involvement. The patient underwent routine postoperative follow-up at our institution and showed no signs of recurrence until the 5th postoperative year. However, his serum p53 antibody titer increased 5 years postoperatively, and careful follow-up using imaging modalities, including CT, was scheduled. No lesions suspected of recurrence were noted over the next 2 years until bilateral pleural effusion was detected on CT in the 7th postoperative year. Cytological examination of the pleural effusion revealed pleural-seeded ESCC cells.

conclusionsAlthough several cases of late recurrence (>5 years) have been previously reported, most have a deeper infiltration depth than that of T2 or pathologically positive lymph nodes. However, patients with lymphatic/vascular involvement, even those with pT1bN0 ESCC, require careful surveillance using imaging modalities and laboratory tests, given the possibility of late recurrence occurring beyond 5 years.

Indexed as

esophageal squamous cell carcinomalate recurrencelymphatic and vascular involvementserum p53 antibody

Identifiers

PMID40985020
PMCPMC12450533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.